Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × ribociclib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 92 Neoplasm Metastasis 5 Neoplasms 4 Breast Diseases 4 Ovarian Neoplasms 3 Neoplasms by Site 3 Carcinoma, Ovarian Epithelial 3 Breast Neoplasms, Male 3 Triple Negative Breast Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Hereditary Sensory and Autonomic Neuropathies 2 Endometrial Neoplasms 2 Breast Cancer Metastatic 2 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Osteitis Deformans 1 Neoplastic Cells, Circulating 1 Mesothelioma 1 Lymphoma 1 Lung Neoplasms 1 Locoregional Recurrence 1 Leukemia 1 Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 HR+HER2- Advanced Breast Cancer 1 HER2-positive Advanced Breast Cancer 1

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06953882 2025-07-14

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡